M John Chapman
Overview
Explore the profile of M John Chapman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
18636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Salinas C, Chapman M
Curr Opin Lipidol
. 2020 Apr;
31(3):132-139.
PMID: 32332433
Purpose Of Review: To critically appraise new insights into the biology of remnant lipoproteins and their putative role in the pathophysiology of atherosclerotic cardiovascular disease, and to compare the atherogenicity...
22.
Chapman M, Orsoni A, Tan R, Mellett N, Nguyen A, Robillard P, et al.
J Lipid Res
. 2020 Apr;
61(6):911-932.
PMID: 32295829
Atherogenic LDL particles are physicochemically and metabolically heterogeneous. Can bioactive lipid cargo differentiate LDL subclasses, and thus potential atherogenicity? What is the effect of statin treatment? Obese hypertriglyceridemic hypercholesterolemic males...
23.
Boren J, Chapman M, Krauss R, Packard C, Bentzon J, Binder C, et al.
Eur Heart J
. 2020 Feb;
41(24):2313-2330.
PMID: 32052833
No abstract available.
24.
Nordestgaard B, Langlois M, Langsted A, Chapman M, Aakre K, Baum H, et al.
Atherosclerosis
. 2020 Jan;
294:46-61.
PMID: 31928713
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory...
25.
Boden W, Bhatt D, Toth P, Ray K, Chapman M, Luscher T
Eur Heart J
. 2019 Dec;
41(24):2304-2312.
PMID: 31872245
The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a...
26.
Langlois M, Nordestgaard B, Langsted A, Chapman M, Aakre K, Baum H, et al.
Clin Chem Lab Med
. 2019 Dec;
58(4):496-517.
PMID: 31855562
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory...
27.
Damask A, Steg P, Schwartz G, Szarek M, Hagstrom E, Badimon L, et al.
Circulation
. 2019 Nov;
141(8):624-636.
PMID: 31707832
Background: Alirocumab, an antibody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OUTCOMES trial (Evaluation of...
28.
Chapman M, Ginsberg H
J Am Coll Cardiol
. 2019 Oct;
74(17):2147-2149.
PMID: 31648706
No abstract available.
29.
Hegele R, Boren J, Ginsberg H, Arca M, Averna M, Binder C, et al.
Lancet Diabetes Endocrinol
. 2019 Oct;
8(1):50-67.
PMID: 31582260
Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in...
30.
Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L, et al.
Eur Heart J
. 2019 Sep;
41(1):111-188.
PMID: 31504418
No abstract available.